Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. May 26, 2014; 6(5): 234-244
Published online May 26, 2014. doi: 10.4330/wjc.v6.i5.234
Published online May 26, 2014. doi: 10.4330/wjc.v6.i5.234
Anti-hypertensive drugs in children and adolescents
Patricia Y Chu, Kevin D Hill, Duke Clinical Research Institute, Durham, NC 27715, United States
Michael J Campbell, Stephen G Miller, Kevin D Hill, Division of Pediatric Cardiology, Department of Pediatrics, Duke University Medical Center, Durham, NC 27715, United States
Author contributions: Chu PY, Campbell MJ, Miller SG and Hill KD contributed to the manuscript literature review, data compilation and writing.
Correspondence to: Kevin D Hill, MD, MSCI, Assistant Professor of Pediatrics in the Division of Pediatric Cardiology, Division of Pediatrics, Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Room 7582, Box 3850 Durham, NC 27705, United States. kevin.hill@duke.edu
Telephone: +1-919-6684686 Fax: +1-919-6687058
Received: December 27, 2013
Revised: January 27, 2014
Accepted: April 16, 2014
Published online: May 26, 2014
Processing time: 175 Days and 17.8 Hours
Revised: January 27, 2014
Accepted: April 16, 2014
Published online: May 26, 2014
Processing time: 175 Days and 17.8 Hours
Core Tip
Core tip: This review focuses on the major clinical trials of anti-hypertensive drugs that have been completed over the past 15 years in response to regulatory initiatives by the United States Food and Drug Administration and the European Medicines Agency. These trials have changed the landscape of anti-hypertensive drug management in children.